NIH Revises Funding Strategy for Young Researchers

The agency plans to ease restrictions on grants to a narrowly defined group of early- and mid-career researchers.

Written byKatarina Zimmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA COMMONS, NATIONAL CANCER INSTITUTEAfter announcing a plan this May to award 400 additional grants each year to early- and mid-career scientists who fall within a specific definition, the National Institutes of Health (NIH) decided to revise its funding strategy at an advisory board meeting last Friday (December 15). The agency now aims to focus funds on researchers who are struggling to keep their labs afloat, regardless of age.

“Age should not matter,” NIH Principal Deputy Director Larry Tabak said in last week’s meeting, according to Science.

For the NIH, this is the third shift in funding policy this year. In May, the agency announced a plan to cap the number of grants a principal investigator could receive in order to create more opportunities for scientists in their early careers and those struggling to keep their labs running. The cap was planned to be set at 21 points on the Grant Support Index, a metric that quantifies grants using a point system rather than dollars. This would equate to three standard R01 grants.

After receiving criticism from senior scientists who expressed concern that the policy would hamper especially productive labs, the NIH abandoned the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies